01104nas a2200145   4500008004100000024000700041245002900048210002800077260001900105300001000124490000700134520073600141100001800877856006300895       2023                        eng d  a0300aDrug Review: Abrocitinib0 aDrug Review Abrocitinib  cSeptember 2023  a14-160 v123 a<p class="rtejustify">Registrations: Abrocitinib had been registered in the following countries United States of America (USA), United Kingdom (U.K.), Canada, and Saudi Arabia (SA). Trade name (USA.); CIBINQO® Registration number (S.A.); Not Available. Insurance Drug Formulary (S.A.); Not covered (28.1.2023). General Information: Registered Company: By Pfizer company. Regulatory Status: R.X. Mechanism of Action: It is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). Indication Approved (Labeled) indication Atopic dermatitis (Moderate to Severe), Refractory to other systemic drug products, including biologics, or when the use of such therapies is inadvisable<sup>.[3]</sup>&nbsp;<strong>Read more..</strong></p>
1 aAlsaab, Juman  uhttps://www.ijphs.org/article/2023/12/1/105530ijpcs2023123